Irshad Karim
@Lion Point Capital, Lp
Latest period2024 - Q3ReportedManaged Assets$44.907MTotal holdings25
Assets growth rate-18.13%Assets growth rate (2-Q avg)-43.74%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Lion Point Capital, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 25 positions.
Assets under management
The assets under management (AUM) of Lion Point Capital, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 44.907M in assets, with a quarterly growth rate of -18.13% and a 2-quarter average growth rate of -43.74%. The portfolio is managed by Irshad Karim, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
INSMInsmed Inc
| 8.49% | $3.811M 52,200 shares@ $73.0 avg price | Decreased -25.78% |
ARDXArdelyx Inc
| 5.68% | $2.549M 370,000 shares@ $6.89 avg price | Decreased -56.8% |
MISTMilestone Pharmaceuticals In
| 5.6% | $2.514M 1.654M shares@ $1.52 avg price | Decreased -29.31% |
KNSAKiniksa Pharmaceuticals Ltd
| 3.42% | $1.534M 61,400 shares@ $24.99 avg price | Decreased -41.35% |
MRNSMarinus Pharmaceuticals Inc
| 2.72% | $1.221M 693,778 shares@ $1.76 avg price | Decreased -67.19% |
SNDXSyndax Pharmaceuticals Inc
| 1.99% | $889,350 46,200 shares@ $19.25 avg price | Decreased -28.92% |
AVDLAvadel Pharmaceuticals Plc
| 1.87% | $839,360 64,000 shares@ $13.12 avg price | Decreased -22.42% |
LUMOLumos Pharma Inc
| 0.35% | $153,209 39,589 shares@ $3.87 avg price | Decreased -56.39% |